Evolution of circulating tumor DNA (ctDNA) profile from first-line (1L) to second-line (2L) therapy in metastatic renal cell carcinoma (mRCC).
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: City Of Hope National Medical Center, University of Alabama at Birmingham, Huntsman Cancer Institute, University of Utah Health Care, Comprehensive Cancer Centers of Nevada, Stanford University, Abramson Cancer Center, University of Pennsylvania, Brigham and Women's Hospital, Guardant (United States), Dana-Farber/Harvard Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2601670541